Compare LEE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | AYTU |
|---|---|---|
| Founded | 1890 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | LEE | AYTU |
|---|---|---|
| Price | $4.65 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 58.9K | ★ 98.6K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | $63,696,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $0.95 |
| 52 Week High | $15.15 | $2.82 |
| Indicator | LEE | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 64.26 | 64.74 |
| Support Level | $3.58 | $2.42 |
| Resistance Level | $4.51 | $2.59 |
| Average True Range (ATR) | 0.44 | 0.15 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 59.24 | 87.50 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.